Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease

Movement Disorders

Volumn 11, Issue 3, 1996, Pages 257-260

  Verhagen Metman, L ^a   Blanchet, P J ^a   De Jong, D ^a   Mouradian, M M ^a   Chase, T N ^a,b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

D1 agonist; D2 antagonist; Dyskinesias; FCE 23884; Parkinson's disease

Indexed keywords

DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; ERGOLINE DERIVATIVE; FCE 23884; LEVODOPA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DYSKINESIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MOTOR SYSTEM; ORAL DRUG ADMINISTRATION; PALLIATIVE THERAPY; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR BLOCKING;

EID: 9244248149     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870110307     Document Type: Article

References (21)

1. Marsden C. Problems with long-term levodopa therapy for Parkinson's disease. Clin Neuropharmacol 1994;17: S32-S44.
2. Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms. Part II. Ann Neurol 1988;24:372-378.
3. Goetz CG, Diederich NJ. Dopaminergic agonists in the treatment of Parkinson's disease. Neurol Clin 1992,10:527-540.
4. Farmitalia Carlo Erba. FCE 23884: investigator's brochure. November 1989.
5. Buonamici M, Mantegani S, Cervini MA, et al. FCE 23884, substrate-dependent interaction with the dopaminergic system. I. Preclinical behavioral studies. J Pharmacol Exp Ther 1991;259:345-355.
6. Buonamici M, Cervini M, Maj R, Mantegani S, Rossi A. A new dopamine agonist in dopamine deprived systems: FCE 23884. Neurochem Int 1992;20:179S-183S.
7. Blanchet P, Bedard PJ, Britton DR, Kebabian JW. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys. J Pharmacol Exp Ther 1993;267:275-279.
8. Temlett JA, Chong PN, Oertel WH, Jenner P, Marsden CD. The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset. Eur J Pharmacol 1988;156:197-206.
9. Temlett JA, Quinn NP, Jenner PG, et al. Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease. Mov Disord 1989;4:261-265.
10. Strolin Benedetti M, Pianezzola E, Basileo G, et al. Preliminary evaluation of the pharmacokinetics of FCE 23884, a new ergoline derivative, in healthy volunteers [Abstract]. 10th International Symposium on Parkinson's Disease. Tokyo, 1991.
11. Davis TL, Brughitta G, Baronti F, Mouradian MM. Acute effects of pulsatile levodopa administration on central dopamine pharmacodynamics. Neurology 1991;41:630-633.
12. Carfagna N, Caccia C, Mantegani S, et al. FCE 23884, substrate-dependent interaction with the dopaminergic system. II. Preclinical biochemical studies. J Pharmacol Exp Ther 1991;259:356-364.
13. Pifl C, Reither H, Hornykiewicz O. Lower efficacy of the dopamine D1 agonist, SKF 38393, to stimulate adenylyl cyclase activity in primate than in rodent striatum. Eur J Pharmacol 1991;202:273-276.
14. Izenwasser S, Katz JL. Differential efficacies of dopamine D1 receptor agonists for stimulating adenylyl cyclase in squirrel monkey and rat. Eur J Pharmacol 1993;246:39-44.
15. Madras BK, Fahey MA, Canfield DR, Spealman RD. D1 and D2 dopamine receptors in caudate-putamen of nonhuman primates (Macaca fascicularis). J Neurochem 1988;51:934-943.
16. Farmitalia Carlo Erba. FCE 23884: MPTP-treated monkeys: investigator's brochure. Milan, Italy, March 1992.
17. Graham WC, Crossman AR, Woodruff GN. Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity I. 6-OHDA lesions of ascending mesencephalic dopaminergic pathways in the rat. Brain Res 1990;514:93-102.
18. Graham WC, Clarke CE, Boyce S, Sambrook MA, Crossman AR, Woodruff GN. Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. II. Unilateral intra-carotid infusion of MPTP in the monkey (Macaca fascicularis). Brain Res 1990;514:103-110.
19. Graham WC, Sambrook MA, Crossman AR. Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism. Brain Res 1993;602:290-303.
20. Seeman P, Niznik HB. Dopamine receptors and transporters in Parkinson's disease and schizophrenia. FASEB J 1990;4: 2737-2744.
21. Alexander GM. Schwartzman RJ, Grothusen JR, Brainard L, Gordon SW. Changes in brain dopamine receptors in MPTP parkinsonian monkeys following L-dopa treatment. Brain Res 1993;625:276-282.